732 Background: Trastuzumab has shown considerable activity in patients with metastatic breast cancer (MBC) that overexpress HER2. However, significant resources have been allocated to finance this new therapy. Due to ever increasing pressures on health care budgets, economic evaluations are requested in order to compare health effects with costs. We aimed to evaluate the cost effectiveness of trastuzumab in patients with metastatic breast cancer in a model based cost effectiveness analysis (CEA). Methods: All available data on trastuzumab in MBC presented at the San Antonio breast cancer conference in late 2003 and all data on the Medline in December 2003 were analysed for life years (LY) gained and quality of life (QoL) with regard to the use of this new monoclonal antibody. Randomised studies comparing standard chemotherapy with or without trastuzumab were focused. The costs were calculated according to Norwegian prices as in January 2003. Results: The LY gained ranged between 0.3–0.7 years. The median cost per patient treated was calculated €44,196 yielding costs per life year saved in the range between €63,137 - €162,417 depending on survival gain and discount rate employed. A sensitivity analysis documented the price of trastuzumab and the survival benefit the two major factors influencing the cost-effectiveness ratio. Conclusions: The economic evaluation indicates trastuzumab not cost effective in metastatic breast cancer. Reduced drug costs and/or improved survival may alter the Conclusion: No significant financial relationships to disclose.